Abdul Waseh Basit

Abdul Waseh Basit is a British pharmacist and Professor of Pharmaceutics at University College London.. He is also the founder of two pharmaceutical spin-out companies from UCL, FabRx Ltd and Intract Pharma. Basit is known for his scientific research in gastroenterology, oral drug delivery, and pharmaceutical 3D printing. 
== Background ==
Basit graduated with a First Class Honours degree in Pharmacy in 1993 from the University of Bath, and undertook his pharmacy pre-registration training at Pfizer Pharmaceuticals, becoming a registered pharmacist in 1994. He joined the School of Pharmacy, University of London (now UCL School of Pharmacy) in 1994 where he completed his PhD in Pharmaceutics and was appointed Professor in Pharmaceutics in 2010.
== Research & career ==
Basit leads a research group that investigates the oral delivery of biologicals, sex differences in the effects of excipients on drug absorption, metabolic potential of the intestinal microbiota on drug behaviour, and the development of modern pharmaceutical manufacturing techniques using three-dimensional (3D) printing. His group pioneered the use of fused deposition modelling (FDM) 3D printing and selective laser sintering (SLS) 3D printing for producing pharmaceutical formulations. Basit holds several granted patents and has invented a number of advanced drug delivery technologies that have been translated into the clinic, including PHLORAL™, DuoCoat™, Opticore™ and Soteria™. To date, Basit has attracted £100 million in investments as a principal investigator (PI) or co-PI. In 2016, Basit was appointed the European editor of the International Journal of Pharmaceutics. He is also an editorial board member of Drug Development and Industrial Pharmacy, AAPS PharmSciTech, Journal of Drug Delivery Science and Technology, and Pharmaceutics (journal). 
== Entrepreneurship ==
=== FabRx ===
In 2014, Basit founded FabRx with Simon Gaisford, Alvaro Goyanes Goyanes, and Bill Lindsay. FabRx is a biotechnology company specialising in the development of 3D printing technology for medicines and medical devices. In 2017, FabRx was awarded the TCT Best Start-Up Award. In 2019, FabRx was awarded over £600,000 from Innovate UK to develop a 3D printer for the production of personalised medicines. In September 2019, FabRx completed a clinical study using its Printlets™ technology to treat children with maple syrup urine disease.
=== Intract Pharma ===
In 2016, Basit founded Intract Pharma with Vipul Yadav and Bill Lindsay. Intract Pharma is a pharmaceutical company that provides licensable technologies for targeted delivery in the gastrointestinal tract. In 2018, Intract Pharma was awarded £1.4 million from Innovate UK to develop a scalable manufacturing process for novel oral antibody products using its Soteria™ technology. In the same year, Intract Pharma received an award from the Bill & Melinda Gates Foundation to fund investigation of its Soteria™ technology as a means to stabilise orally-administered therapeutic antibodies to fight against diarrhoeal diseases in children in the developing world. In December 2018, in collaboration with Tillots Pharma AG, Intract Pharma launched Yaldigo®/Asacol 1600, a medicine used for the treatment of ulcerative colitis.
== Awards & Honours ==
Selected awards received by Basit include:
* 2004 American Association of Pharmaceutical Scientists Young Investigator Award in Pharmaceutics and Pharmaceutical Technology.
* 2014 Academy of Pharmaceutical Sciences AstraZeneca Award.
* 2017 Academy of Pharmaceutical Sciences Science Chairman.
* 2019 GlaxoSmithKline Innovative Science Award.
* 2019 Web of Science Group World’s Most Highly Cited Researchers.
== Books ==
* 3D Printing of Pharmaceuticals
== References ==
== External links ==
* FabRx Ltd
* Intract Pharma
* Abdul Basit's UCL Institutional Research Information Service Profile
* Basit Research Group Webpage
Category:British people
Category:British pharmacists
Category:British academics